News | April 27, 2024
AstraZeneca 1Q 2024 revenue up 19% to US$ 12,679 million
Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery
Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery
Additional data in pregnant adults who are Virologically suppressed reinforce safety and tolerability profile of Biktarvy in broad range of people with HIV
Laurus Labs has reported total income of Rs. 1,458.20 crores during the period ended March 31, 2024
The joint venture will help JV Partners combine their strengths and grow their complementary nutraceuticals portfolios
Sales reflect continued strong growth in oncology and vaccines
Syngene International has reported total income of Rs. 933 crores during the period ended March 31, 2024
One form of thalidomide has the intended sedative effect but the opposite mirror-image form interferes with foetal development
ALPHA Phase III trial showed first-in-class, oral, Factor D inhibitor as add-on to Ultomiris or Soliris improved haemoglobin levels and reduced anaemia and fatigue
Desidustat, administered orally is a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in Chronic Kidney Disease (CKD) patients
Commercial terms include research funding and milestones and/or royalty payments to Evotec based on the success of the program
Subscribe To Our Newsletter & Stay Updated
